SERA PROGNOSTICS INC-A (SERA) Stock Fundamental Analysis
USA - NASDAQ:SERA - US81749D1072 - Common Stock
3.75 USD
+0.01 (+0.27%)
SERA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. SERA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SERA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
SERA had negative earnings in the past year.
SERA had a negative operating cash flow in the past year.
In the past 5 years SERA always reported negative net income.
SERA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
SERA's Return On Assets of -29.27% is fine compared to the rest of the industry. SERA outperforms 67.60% of its industry peers.
With a decent Return On Equity value of -37.10%, SERA is doing good in the industry, outperforming 73.60% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -29.27% | ||
| ROE | -37.1% | ||
| ROIC | N/A |
ROA(3y)-40.43%
ROA(5y)-55.85%
ROE(3y)-55.05%
ROE(5y)-196.88%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SERA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SERA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SERA has been increased compared to 1 year ago.
The number of shares outstanding for SERA has been increased compared to 5 years ago.
The debt/assets ratio for SERA has been reduced compared to a year ago.
2.2 Solvency
SERA has an Altman-Z score of -0.99. This is a bad value and indicates that SERA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of SERA (-0.99) is comparable to the rest of the industry.
SERA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.99 |
ROIC/WACCN/A
WACC8.64%
2.3 Liquidity
A Current Ratio of 1.73 indicates that SERA should not have too much problems paying its short term obligations.
SERA's Current ratio of 1.73 is on the low side compared to the rest of the industry. SERA is outperformed by 79.03% of its industry peers.
SERA has a Quick Ratio of 1.73. This is a normal value and indicates that SERA is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of SERA (1.73) is worse than 78.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.73 | ||
| Quick Ratio | 1.73 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 13.27% over the past year.
The Revenue has been growing slightly by 2.86% in the past year.
The Revenue has been growing by 14.00% on average over the past years. This is quite good.
EPS 1Y (TTM)13.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36%
Revenue 1Y (TTM)2.86%
Revenue growth 3Y-1.27%
Revenue growth 5Y14%
Sales Q2Q%-29.17%
3.2 Future
SERA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.82% yearly.
SERA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 195.78% yearly.
EPS Next Y21.7%
EPS Next 2Y7.96%
EPS Next 3Y14.08%
EPS Next 5Y8.82%
Revenue Next Year118.18%
Revenue Next 2Y255.5%
Revenue Next 3Y236.73%
Revenue Next 5Y195.78%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SERA. In the last year negative earnings were reported.
Also next year SERA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as SERA's earnings are expected to grow with 14.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.96%
EPS Next 3Y14.08%
5. Dividend
5.1 Amount
No dividends for SERA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:SERA (10/28/2025, 8:21:41 PM)
3.75
+0.01 (+0.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners64.87%
Inst Owner Change0.17%
Ins Owners2.66%
Ins Owner Change2.19%
Market Cap142.72M
Revenue(TTM)108.00K
Net Income(TTM)-32731000
Analysts85
Price TargetN/A
Short Float %1.62%
Short Ratio7.45
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.52%
Min EPS beat(2)14.75%
Max EPS beat(2)30.28%
EPS beat(4)2
Avg EPS beat(4)8.99%
Min EPS beat(4)-6.95%
Max EPS beat(4)30.28%
EPS beat(8)6
Avg EPS beat(8)11.42%
EPS beat(12)10
Avg EPS beat(12)13.93%
EPS beat(16)11
Avg EPS beat(16)5.03%
Revenue beat(2)0
Avg Revenue beat(2)-63.9%
Min Revenue beat(2)-74.36%
Max Revenue beat(2)-53.43%
Revenue beat(4)1
Avg Revenue beat(4)-34.37%
Min Revenue beat(4)-74.36%
Max Revenue beat(4)56.86%
Revenue beat(8)1
Avg Revenue beat(8)-48.2%
Revenue beat(12)3
Avg Revenue beat(12)-35.67%
Revenue beat(16)3
Avg Revenue beat(16)-38.4%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14.89%
EPS NY rev (1m)0%
EPS NY rev (3m)14.61%
Revenue NQ rev (1m)-15%
Revenue NQ rev (3m)-37.04%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-35.14%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1321.53 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.62 | ||
| P/tB | 1.64 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.85
EYN/A
EPS(NY)-0.83
Fwd EYN/A
FCF(TTM)-0.71
FCFYN/A
OCF(TTM)-0.69
OCFYN/A
SpS0
BVpS2.32
TBVpS2.29
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -29.27% | ||
| ROE | -37.1% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-40.43%
ROA(5y)-55.85%
ROE(3y)-55.05%
ROE(5y)-196.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 76.79% | ||
| Cap/Sales | 615.74% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.73 | ||
| Quick Ratio | 1.73 | ||
| Altman-Z | -0.99 |
F-Score3
WACC8.64%
ROIC/WACCN/A
Cap/Depr(3y)83.45%
Cap/Depr(5y)92.8%
Cap/Sales(3y)588.1%
Cap/Sales(5y)777.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36%
EPS Next Y21.7%
EPS Next 2Y7.96%
EPS Next 3Y14.08%
EPS Next 5Y8.82%
Revenue 1Y (TTM)2.86%
Revenue growth 3Y-1.27%
Revenue growth 5Y14%
Sales Q2Q%-29.17%
Revenue Next Year118.18%
Revenue Next 2Y255.5%
Revenue Next 3Y236.73%
Revenue Next 5Y195.78%
EBIT growth 1Y-4.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.58%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y8.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.86%
OCF growth 3YN/A
OCF growth 5YN/A
SERA PROGNOSTICS INC-A / SERA FAQ
What is the fundamental rating for SERA stock?
ChartMill assigns a fundamental rating of 3 / 10 to SERA.
Can you provide the valuation status for SERA PROGNOSTICS INC-A?
ChartMill assigns a valuation rating of 0 / 10 to SERA PROGNOSTICS INC-A (SERA). This can be considered as Overvalued.
Can you provide the profitability details for SERA PROGNOSTICS INC-A?
SERA PROGNOSTICS INC-A (SERA) has a profitability rating of 1 / 10.
What is the financial health of SERA PROGNOSTICS INC-A (SERA) stock?
The financial health rating of SERA PROGNOSTICS INC-A (SERA) is 5 / 10.
What is the expected EPS growth for SERA PROGNOSTICS INC-A (SERA) stock?
The Earnings per Share (EPS) of SERA PROGNOSTICS INC-A (SERA) is expected to grow by 21.7% in the next year.